US5851552A - Delivery of controlled-release system(s) - Google Patents
Delivery of controlled-release system(s) Download PDFInfo
- Publication number
- US5851552A US5851552A US08/698,907 US69890796A US5851552A US 5851552 A US5851552 A US 5851552A US 69890796 A US69890796 A US 69890796A US 5851552 A US5851552 A US 5851552A
- Authority
- US
- United States
- Prior art keywords
- drugs
- composition
- masses
- agents
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/02—Apparatus specially adapted for manufacture or treatment of sweetmeats or confectionery; Accessories therefor
- A23G3/10—Candy-pulling machines ; Processes or apparatus for making cotton candy or candy floss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B30—PRESSES
- B30B—PRESSES IN GENERAL
- B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
- B30B11/02—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using a ram exerting pressure on the material in a moulding space
- B30B11/027—Particular press methods or systems
Definitions
- the present invention relates to controlled release systems, and, in particular to improved delivery of controlled release system or systems.
- Controlled-release is used herein to describe a method and composition for making an active ingredient available to the biological system of a host. Controlled-release includes the use of instantaneous release, delayed release, and sustained release. "Instantaneous release” is self-explanatory in that it refers to immediate release to the biosystem of the host. "Delayed release” means the active ingredient is not made available to the host until some time delay after administration. (Dosages are usually administered by oral ingestion in the context of the present invention, although other forms of administration are not precluded from the scope of the present invention). "Sustained Release” generally refers to release of active ingredient whereby the level of active ingredient available to the host is maintained at some level over a period of time.
- the active-ingredient can be associated physically and/or chemically with a surfactant, a chelating agent, etc.
- the active ingredient can be masked by a coating, a laminate, etc.
- the present invention contemplates delivery of a controlled-release system which utilizes one or more of the "release" methods and compositions.
- the present invention can be an element of the release method and/or composition, especially with respect to instantaneous release systems(s).
- SR sustained release
- polymeric capsules with a solid, liquid, suspension or gel containing a therapeutic agent which is slowly released by diffusion through the capsule walls.
- Heterogeneous matrices for example compressed tablets, control the release of their therapeutic agents either by diffusion, erosion of the matrix or a combination of both.
- Other SR systems focus on the fabrication of laminates of polymeric material and therapeutic agent which are then formed into a sandwich, relying on diffusion or erosion to control release of the therapeutic agent.
- Liquid-Liquid encapsulated in a viscous syrup-like solution of polymer have also been known to be useful in controlling release of the therapeutic agent. Additionally, it is generally known that heterogeneous dispersions or solution of therapeutic agents in water-swellable hydrogel matrices are useful in controlling the release of the agent by slow surface-to-center swelling of the matrix and subsequent diffusion of the agent from the water-swollen part of the matrix.
- the dosage form During dissolution of a controlled-release matrix tablet, the dosage form generally remains as a non-disintegrating, slowly eroding entity from which the therapeutic agent leaches out, through a diffusion controlled process.
- Conventional SR formulations are generally designed to release their actives over an extended period of time, usually 8-24 hours.
- Conventional SR formulations use waxes or hydrophilic gums as the primary drug carriers to prolong the release of the active ingredients.
- the drug is dispersed in the wax matrix in the molten state.
- waxes and waxy materials used in pharmaceutical formulations are carnauba wax, spermaceti wax, candellila wax, cocoa butter, cetosteryl alcohol, beeswax, partially hydrogenated vegetable oils, ceresin, paraffin, myristyl alcohol, stearyl alcohol, cetylalcohol and stearic acid. They are generally used in amounts of about 10 to about 50% by weight of the total formulation.
- Hydrophilic gums have also been known to be reasonably effective as SR carriers for both high-dose and low-dose drugs.
- Typical hydrophilic gums used as SR carrier materials are acacia, gelatin, tragacanth, veegum, xanthan gum, carboxymethyl cellulose (CMC), hydroxypropl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC) and hydroxyethyl cellulose (HEC). Generally these materials are present in amounts of about 10 to 50% by weight of the final formulation.
- Starch USP (potato or corn) is commonly used as a component in conventional tablet or hard shell capsule formulations. It generally functions in conventional applications as a diluent or as a disintegrant in oral dosage forms. Starch paste is also often used as a binder in these products.
- modified starches such as carboxymethyl starch currently marketed under the trade name Explotab or Primojel are used both in tablets and capsules as disintegrating agents. The literature discloses that native and modified starches are useful in promoting rapid release of drugs from solid oral dosage forms. Additionally, native starch has been used in some instances as a binder to produce granulations of active drug substances.
- pregelatinized starch has been reported as being useful as an SR matrix for theophylline formulations by Herman and Remon, "Modified Starches as Hydrophilic Matrices for Controlled Oral Deliver; III Evaluation of Sustained-Release Theophylline Formulations Based on Thermal Modified Starch Matrices in Dogs," in International Journal of Pharmaceutics,63 (1990) 201-205.
- modified starch were mixed with anhydrous theophylline (60:40 W/W) as well as with silicon dioxide (Aerosil 200) and sodium benzoate.
- OROS SR delivery system
- Alza Corporation involves laser drilling through a tablet to create a passage for the release of the drug from the tablet core.
- controlled-release systems have been provided in the form of beads or particles which are packaged in a gelatin capsule for oral dosage. This method of delivery of the controlled-release system prevents damage to the coating on the beads.
- an oral dosage form in many cases it may be desirable to provide an oral dosage form as a tablet.
- chewing of the tablet may often rupture the coatings on the active ingredient. This results in unpredictable release rates and delivery to the biosysteri of the host.
- controlled-release components when controlled-release components are incorporated in compression tablets, the extremely high pressure required to tablet can be expected to rupture the coatings. Consequently, the compression tablet form of delivery is not usable, or extremely tough elastic coatings are required to withstand normal tablet pressures.
- the present invention overcomes the disadvantages of the prior art by offering a simple and inexpensive means of incorporating a controlled-release system in a unit dosage form which avoids the shortcomings normally associated with unit dosage delivery systems.
- a method of preparing a rapid or quick dissolve comestible unit is provided by mixing uncured shearform matrix and a controlled-release system, molding the mixture to form a unit dosage form, and curing the shearform matrix.
- the shearform matrix includes a crystallization enhancer and/or a binding aid.
- controlled-release system can include a component selected from the group consisting of instantaneous release components, delayed release component(s), sustained release component(s), and combination thereof.
- Instantaneous release components can be provided by simply inclusion of raw active as an ingredient with the shearform matrix or can include a dispersion enhancer such as a surfactant, etc.
- a delayed release component is a component which has been treated by coating or otherwise to provide delayed bio-availability in the host.
- Such systems include, but are not limited to, polymeric coatings, biodegradable coatings, etc.
- Sustained release components are components which have been designed to provide a constant dosage release to the biosystem over a period of time. The present invention also includes combinations thereof.
- the shearform matrix used to form dosage units in accordance with the invention can be made with flavors and/or sweeteners included in the feedstock used to make the matrix.
- Flavors can be chosen from natural and synthetic flavoring liquids.
- Sweeteners are those materials which provide sweetness to the matrix in addition to sweetness which is provided by the carrier material used to form the matrix, e.g., sucrose.
- the mixture can be molded by being introduced in a unit dosage well and tamping the mixture therein.
- the tamped mixture is then cured by being subjected to environmental conditions of heat, moisture, and pressure which induce crystallization.
- the unit can be cured by increasing the heat under substantially constant moisture condition.
- the heat can be increased by subjecting the tamped unit to microwave energy.
- effervescent disintegration agent includes compounds which evolve gas.
- the preferred effervescent agents evolve gas by means of chemical reactions which take place upon exposure of the effervescent disintegration agent to saliva in the mouth.
- the agent or agents can be included in several ways in the units of the present invention. First of all the agents can be incorporated in the matrix by mixing with the feedstock prior to flash flow processing. Alternatively, the entire effervescent agent can be mixed with the shearform matrix after it has been produced by flash flow techniques.
- one part of the agent can be included in the feedstock which is flash flow processed while the other part of the agent can be incorporated after flash flow processing.
- the effervescent disintegration agent provides for controlled and rapid disintegration of the tablet when placed in the mouth and provides for a positive organoleptic sensation by the effervescent action in the mouth.
- the texture, speed and sensation of disintegration can especially be adapted for use by children in combination with taking one or more of the medicaments contemplated for use in the present invention.
- Tamping is used herein to mean that the mixture is subjected to compression pressure of less than about 500 lbs. per sq. in. (psi), preferably less than 250 psi, and most preferably from about 20 to about 100 psi.
- Another method of identifying the compression force required to mold uncured matrix in accordance with the present invention is by identifying the density resulting from tamping.
- the product of the present invention should be compressed in its uncured condition to a density of not greater than about 1.2, preferably not greater than about 0.8, and most preferably not greater than about 0.65. In one most preferred embodiment, the density of the finished product is between 0.25 and 0.40.
- the product prepared in accordance with the method set forth above can dissolve in the mouth of the consumer in less than 10 seconds. Usually, well made product produced in accordance with this process will dissolve within less than 5 seconds, and, most preferably less than 3 seconds. The most highly dissoluble units have been described as literally "exploding" in the mouth.
- the present invention also includes a composition for delivering a controlled-release system wherein the controlled-release system is incorporated in a molded saccharide-based crystalline structure.
- the composition also includes the saccharide-based structure which has a bi-dimensionally stabilized crystalline sugar.
- the sugar is produced by forming a sugar crystalline frame from an outer portion of an amorphous shearform sugar mass, and subsequently converting the remaining portion of the mass to a substantially completely crystalline structure.
- the product is preferably monodispersed and is also preferably microcrystalline.
- the shearform mass can also include an additive which is co-crystallized in a crystalline product.
- the amorphous shearform mass is substantially rod-shaped, and has two dimensions lying in a cross-sectional plane of the rod. The single dimension extends along a linear axis of the rod.
- the monodispersed structurally stabilized cross-section does not exceed 50 ⁇ m, and preferably does not exceed 15 ⁇ m.
- Yet another manifestation of the first embodiment of the present invention is a method of administering an active ingredient to a human host.
- the method includes ingesting a quick dissolve comestible unit prepared by the method of the present invention, i.e., mixing uncured shearform matrix and an active ingredient, followed by molding a unit dosage and curing the shearform matrix in the unit dosage form.
- the next step requires the host to retain the quick dissolve unit in the oral cavity for a time sufficient to contact the unit with water while in the oral cavity.
- the human host introduces water to the oral cavity while the unit is retained therein to enhance dissolution of the dosage unit.
- a rapidly dissolving dosage unit can be manufactured on a continuous basis and even prepared for shipment to the consumer in a single manufacturing line.
- the product can be made to provide the stunning sensation of exploding in the oral cavity upon ingestion by the consumer.
- a method of preparing a comestible unit which quickly disperses in the mouth of the consumer includes initiating crystallization of shearform matrix either before or after combining the shearform matrix with a delivery system, as defined hereinabove, to form flowable, compactible micro-particulates.
- the combination which includes at least partially crystallized shearform matrix, is then compacted to form the comestible unit.
- a crystallization/binding promoter is used to enhance the formation of flowable, compactible micro-particulates.
- the crystallization/binding promoter can be selected from the group consisting of an alcohol, such as ethanol, polyvinylpyrrolidone and a combination thereof.
- the promoter can also be a surface active agent. Surface active agents can be added to feedstock used to form the matrix. Alternatively, polydextrose can be used as a promoter by inclusion in the feedstock.
- the shearform matrix can be prepared by flash flow processing feedstock which includes saccharide based material as a carrier component.
- saccharide based material as a carrier component.
- Sucrose is a preferred carrier, and it can be combined with other saccharide based carrier components, such as dextrose, and sugar alcohols, such as sorbitol, mannitol, etc.
- the feedstock can also include a crystallization enhancer such as a surfactant, e.g., tweens, spans, etc.
- a medium compression force can be used without fear of disrupting the disintegratability of the unit.
- the compression force need not exceed ten (10) Strong Cobb Units ("SCU"), and preferably does not exceed medium compression forces of between six (6) and eight (8) SCU's.
- SCU Strong Cobb Units
- a low compression force can also be used. In either event, tablets produced according to the invention can be made low density and easily disintegrated.
- Another method of identifying the compression force required to mold uncured matrix in accordance with the present invention is by identifying the density resulting from compacting.
- the product of the present invention should be compacted to a density of not greater than about 1.2, and preferably not greater than about 0.8.
- effervescent disintegration agent includes compounds which evolve gas.
- the preferred effervescent agents evolve gas by means of chemical reactions which take place upon exposure of the effervescent disintegration agent to saliva in the mouth.
- the agent or agents can be included in several ways in the units of the present invention. First of all, the agents can be incorporated in the matrix by mixing with the feedstock prior to flash flow processing. Alternatively, the entire effervescent agent can be mixed with the shearform matrix after it has been produced by flash flow techniques.
- one part of the agent can be included in the feedstock which is flash flow processed while the other part of the agent can be incorporated after flash flow processing.
- the effervescent disintegration agent provides for controlled and rapid disintegration of the tablet when placed in the mouth and provides for a positive organoleptic sensation by the effervescent action in the mouth.
- the texture, speed and sensation of disintegration can especially be adapted for use by children in combination with taking one or more of the medicaments contemplated for use in the present invention.
- the present invention also includes a composition for delivering a controlled-release delivery system wherein the active ingredient is incorporated in a molded saccharide-based crystalline structure.
- the composition also includes the saccharide-based structure which has a bi-dimensionally stabilized crystalline sugar as defined hereinbefore.
- Yet another manifestation of this embodiment is a method of administering an active ingredient to a human host.
- the method includes ingesting a quick dissolve comestible unit prepared by the method of the present invention.
- the next step requires the host to retain the quick dissolve unit in the oral cavity for a time sufficient to contact the unit with water while in the oral cavity.
- the human host introduces water to the oral cavity, while the unit is retained therein, to enhance dissolution of the dosage unit.
- another feature includes reinforcing particles which inhibit destruction of components of the controlled-release system.
- Reinforcing particles have a size, shape, and hardness which are intended to withstand destructive pressure of an inadvertant bite by the consumer.
- reinforcing particles can have a size which is up to 100 times larger that controlled-release components.
- the hardness is preferable greater than the hardness of the components of the controlled-release system.
- the shape is preferably one which does not detract from the texture and mouthfeel of the dosage unit during ingestion.
- a rapidly dispersible comestible unit can be manufactured for shipment and sales to consumers.
- the method of the present invention is such that the manufacturing can proceed on a continuous commercial scale.
- a unit can be formed which is durable and can withstand handling associated with packaging and distribution.
- the component(s) of the controlled-release system can be made available to the host virtually without interference with ingredients therein.
- the present invention is a method of making comestible units which disintegrate quickly in the mouth of the consumer.
- the units produced in accordance with the present invention disintegrate nearly instantaneously.
- these units or tablets are capable of being manufactured so that they can be handled for packaging and distribution without deterioration of the integrity of the comestible units.
- comestible units such as tablets have been made primarily by compressing feedstock under extremely high-pressure in order to provide the necessary hardness for handling required during packaging and distribution. Consequently, prior art tablets so produced are limited in that their high density reduces the capability of making them quickly disintegratable in the mouth. High density packing resulting from the high compression hinders the disintegration and wetting of the interior portion of the tablet. This aspect of the prior art has been improved by the technology disclosed in parent U.S. application Ser. No. 194,682, filed on Feb. 10, 1994.
- the first step of the procedure of the first embodiment is to mix an uncured shearform matrix and a controlled-release system which includes an active ingredient, to prepare for molding a unit dosage.
- Shearform matrix in the present invention means a matrix produced by subjecting a feedstock which contains a carrier material to flash flow processing.
- Flash flow processing can be accomplished several ways. Flash-heat and flash-shear are two processes which can be used.
- the feedstock material is heated sufficiently to create an internal flow condition which permits part of the feedstock to move at subparticle level with respect to the rest of the mass and exit openings provided in the perimeter of a spinning head.
- the centrifugal force created in the spinning head flings the flowing feedstock material outwardly from the head so that it reforms with a changed structure.
- the force necessary to separate and discharge flowable feedstock is centrifugal force which is produced by the spinning head.
- One preferred apparatus for implementing a flash heat process is a "cotton candy" fabricating type of machine.
- the spinning machine used to achieve a flash-heat condition is a cotton candy machine such as the Econo-Floss Model 3017 manufactured by Gold Medal Products Company of Cincinnati, Ohio. Any other apparatus or physical process which provides similar forces and temperature gradient conditions can also be used.
- a shearform matrix is formed by raising the temperature in the feedstock material which includes a non-solubilized carrier, such as a saccharide-based material until the carrier undergoes internal flow upon application of a fluid shear force.
- the feedstock is advanced and ejected while in internal flow condition, and subjected to disruptive fluid shear force to form multiple parts or masses which have a morphology different from that of the original feedstock.
- the multiple masses are cooled substantially immediately after contact with the fluid shear force and are permitted to continue in a free-flow condition until solidified.
- the flash shear process can be carried out in an apparatus which has means for increasing the temperature of a non-solubilized feedstock and means for simultaneously advancing it for ejection.
- a multiple heating zone twin screw extruder can be used for increasing the temperature of the non-solubilized feedstock.
- a second element of the apparatus is an ejector which provides the feedstock in a condition for shearing.
- the ejector is in fluid communication with the means for increasing the temperature and is arranged at a point to receive the feedstock while it is in internal flow condition.
- the ejector is preferably a nozzle which provides high pressure ejection of the feedstock material. See co-pending commonly-owned U.S.
- the feedstock for producing shearform matrix includes a carrier material.
- the carrier material can be selected from material which is capable of undergoing both physical and/or chemical changes associated with flash-flow processing. Materials useful as matrices may be chosen from those carbohydrates which are capable of forming free-form agglomerates upon being processed.
- Preferred materials useful as matrices may be chosen from such classes as “sugars".
- “Sugars” are those substances which are based on simple crystalline mono- and di-saccharide structures, i.e., based on C 5 and C 6 sugar structures.
- “Sugars” include sucrose, fructose, lactose, maltose, and sugar alcohols such as sorbitol, mannitol, maltitol, etc.
- the preferred choice of sugar in the present invention is sucrose.
- Preferred combinations of sugars includes sugars as used herein in combination with other mono-, di-, tri-, and polysaccharides up to 50% of the total amount, preferably up to 30% and most preferably up to 20%.
- a shearform product is used in the technique of the present invention to obtain the new sugar product.
- a shearform sugar product is a substantially amorphous sugar which results from subjecting sugar to heat and shear sufficient to transform crystalline (usually granulated) sugar to amorphous sugar without the use of a solution.
- a shearform sugar product is characterized as a sugar product resulting from a non-solubilized sugar. It is the starting material for forming the unique crystalline product of the present invention.
- carrier materials can be used, but preferably in combination with sugar - - - not as a total replacement.
- Maltodextrins are an example of other carrier materials. Maltodextrins include those mixtures of carbohydrates resulting from hydrolysis of a saccharide feedstock which are described as solids having a DE of up to and including 65.
- the feedstock can also include maltooligo-saccharides produced by selective hydrolysis of cornstarch followed by removal of high and low molecular weight compounds.
- maltooligo-saccharides produced by selective hydrolysis of cornstarch followed by removal of high and low molecular weight compounds.
- the general description of malto-oligosaccharides as contemplated herein is set forth in co-pending U.S. application Ser. No. 07/847,595 filed Mar. 5, 1992.
- Polydextrose is also contemplated for use as a carrier.
- Polydextrose is a non-sucrose, essentially non-nutritive carbohydrate substitute. It can be prepared through polymerization of glucose in the presence of polycarboxylic acid catalyst and polyols.
- polydextrose is known to be commercially available in three forms: polydextrose A and polydextrose K, which are powdered solids, and polydextrose N supplied as a 70% solution. Each of these products also contain some low molecular weight components, such as glucose, sorbitol and certain oligomers.
- Applicants incorporate herein the contents of co-pending, U.S. application Ser. No. 07/881,612 filed May 12, 1992.
- each of the carriers are used primarily in combination with sugars, and not as a total replacement.
- compositions which can be incorporated into the feedstock to enhance the shearform matrix include flavors and sweeteners (other than the carrier itself).
- Flavors may be chosen from natural and synthetic flavoring liquids.
- An illustrative list of such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combination thereof.
- a non-limiting representative list of examples includes citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot or other fruit flavors.
- aldehydes and esters such as benzaldehyde (cherry, almond), citral, i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime) decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), adlehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanal (green fruit), and 2-dodecenal (citrus, mandarin), mixtures thereof and the like.
- aldehydes and esters such as benzaldehyde (cherry, almond), citral, i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime) decanal (orange, lemon), aldehyde C-8 (citrus fruits
- the sweeteners may be chosen from the following non-limiting list: glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, xylitol, and the like.
- hydrogenated starch hydrolysates and the synthetic sweetener 3,6-dihydro-6-methyl-1-1-1,2,3-oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame-K), and sodium and calcium salts thereof.
- Other sweeteners may also be used.
- ingredients can also be used in the present invention either during the mixing stage, during the agglomeration stage, or after the agglomeration stage.
- Such ingredients are ingredients which are useful in tabletting such as glidants which adhere to cohesive material and enhance flow properties. Flow property is enhanced by reducing interparticle friction which otherwise exists.
- Glidants which can be used includes starch, talc, magnesium and calcium stearate, zinc stearate, dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, and silica arogels.
- color additives can be used in preparing tablets.
- Such color additives include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C).
- FD&C drug and cosmetic colors
- D&C drug and cosmetic colors
- Ext. D&C external drug and cosmetic colors
- These colors are dyes, their corresponding lakes, and certain natural and derived colorants. Lakes are dyes absorbed on aluminum hydroxide.
- Yet a further embodiment of the present invention includes the use of an effervescent disintegration agent. Its action can aid in the masking of objectionable taste of active ingredients such as vitamins, medicines and/or minerals, etc. It is generally believed that the positive organoleptic sensation achieved by the effervescent action in the mouth, the texture, speed and sensation of disintegration aids in masking undesirable flavor notes in the mouth.
- the effervescent disintegration agent may include at least one acid selected from the group consisting of citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides and acid salts and mixtures thereof, and at least one base selected from the group consisting of carbonate salts, bicarbonate salts and mixtures thereof.
- effervescent refers to those agents which evolve gas, and the bubble or gas generating the action is most often the result of the reaction of a soluble acid source and an alkali metal carbonate or carbonate source.
- the reaction of these two general classes of compounds produces carbon dioxide gas upon contact with water included in saliva.
- Carbonate sources include dry solid carbonate and bicarbonate salts such as sodium bicarbonate, sodium carbonate, potassium bicarbonate and potassium carbonate, magnesium carbonate and sodium sesequicarbonate, sodium glycine carbonate, L-lysine carbonate, arginine carbonate and amorphous calcium carbonate. While the food acids can be those indicated above, acid anhydrides of the above-described acids may also be used.
- Acid salts may include sodium, dihydrogen phosphate, disodium dihydrogen pyrophosphate, acid citrate salts and sodium acid sulfite.
- Other source of effervescence can be included and the present invention is not limited to those specifically set forth herein.
- the ingredients of the effervescent agent can be included in one of at least three different ways.
- the first method includes incorporating the entire effervescent agent in the feedstock which is used to form the shearform product.
- the second manner of incorporating an effervescent disintegrating agent is to include the entire agent as an additive which is mixed with shearform matrix after it is formed.
- the third method contemplates incorporating one portion of the disintegrating agent in the shearform matrix and another portion of the disintegrating agent as an additive after formation of the shearform matrix material. The artisan will determine the best way to preserve the agent for its disintegrative and effervescent properties upon ingestion by the host.
- the shearform matrix used in the inventive process must be uncured before it is molded.
- Uncured means amorphous or having a degree of amorphousness which enables the formation of a dosage unit upon curing.
- “Curing” means transforming the matrix from amorphous to crystalline while being sufficiently bound to produce a stable structure.
- Crystallization modifiers can be added to the feedstock before flash flow processing, such modifiers include, but are not limited to, surfactants (SpansTM and TweensTM), dextrose, polyethylene glycol (PEG), polypropylene glycol (PPG), etc. These modifiers generally provide controlled acceleration of crystallization while the matrix is bound.
- Crystallization modifiers enhance the formation of a crystalline frame and the conversion of the remaining mass. Enhancement as used with respect to the process of the present invention principally means acceleration of the process. Enhancement also includes contribution to the strength of the crystalline structure, and predictability of results. Other benefits such as reduced-size product also is achieved by use of crystallization modifiers.
- Crystallization modifiers which are preferably added to sugars before being processed to amorphous shearform mass (or can be coated on the sugar), are used to affect the rate of crystallization.
- Water itself is a crystallization modifier, and is preferably included in the amorphous shearform sugar mass in an amount of between about 0.5% to about 2.0%.
- Non-saccharide hydrophilic organic materials are also used as crystallization modifiers. Even though some NSHMs are surfactants, other materials can be used. Materials found to be most effective have a hydrophilic to lipid balance (HLB) of 6 or greater, i.e., they have the same degree of hydrophilicity as surfactants characterized by degree of HLB.
- Such materials include, but are not limited to anionic, cationic, zwitterionic surfactants as well as neutral materials which have an HLB of six (6) or greater.
- Preferred NSHMs are hydrophilic materials having polyethylene oxide linkages. Also, the preferred NSHM's have a molecular weight of at least 200 and preferably at least 400.
- Lecithin is one surface active agent for use in the present invention. Lecithin can be included in the feedstock in an amount of from about 0.25 to about 2.00% by weight.
- Other surface active agents include, but are not limited to, the SpansTM and TweensTM which are commercially available from ICI Americas Inc.
- CarbowaxTM is yet another crystallization modifier which is very useful in the present invention.
- TweensTM or combinations of surface active agents are used to achieve the desired HLB.
- the process of the present invention requires mixing an additive with the uncured shearform matrix.
- the shearform matrix is in the form of a floss, it is preferably chopped first to reduce the volume of the product without compressing it.
- the additive can be any ingredient or ingredients needed to supply the dosage unit with the required characteristics.
- the primary ingredients are medicinal substances.
- the controlled-delivery system is combined before or after initiating crystallization.
- “Initiating crystallization” in the present invention means to induce crystallization.
- Shearform matrix used in the present invention contains a substantial amount of amorphous sugar.
- Crystallization can be initiated several ways.
- crystallization promoters can be included in the feedstock used to make the shearform matrix.
- Crystallization promoters include surface active agents such as TweensTM, SpansTM, and polydextrose, and mixtures thereof. Crystallization can also be initiated by adding a crystallization agent to the matrix before or after combining with an additive. Therefore, initiating crystallization in the present invention can occur before or after combining with the additive.
- “Combining" an additive with shearform matrix to form flowable, compactible micro-particulates means to add and mix an additive before or after initiating crystallization to form a medium which consists of micro-particulates.
- Micro-particulates are discreet entities which appear to "roll” readily or “flow” in response to force of gravity and/or agitation. On a macroscopic scale micro-particulates appear as a flowable mass or medium. Consequently, the medium can be easily used in tabletting machinery without clogging and/or creation of undue dust in the ambient atmosphere.
- the shearform matrix of the present invention is retrieved from processing, and generally "chopped" before combining with the additive.
- the additive can be any ingredient or ingredients needed to supply the comestible unit with the required characteristics.
- the primary ingredient of the additive is one or more medicinal substances.
- Medicinal substances which can be used in the present invention are varied.
- the medicinal substances can be encapsulated for controlled release.
- a non-limiting list of medicinal substances is as follows: antitussives, antihistamines, decongestants, alkaloids, mineral supplements, laxatives, vitamins, antacids, ion exchange resins, anti-cholesterolemics, anti-lipid agents, antiarrhythmics, antipyretics, analgesics, appetite suppressants, expectorants, anti-anxiety agents, anti-ulcer agents, anti-inflammatory substances, coronary dilators, cerebral dilators, peripheral vasodilators, anti-infectives, psycho-tropics, antimanics, stimulants, gastrointestinal agents, sedatives, antidiarrheal preparations, anti-anginal drugs, vasodialators, anti-hypertensive drugs, vasoconstrictors, migraine treatments, antibiotics, tranquilizers, anti-psychotics, antitumor drugs
- antacids Especially preferred active ingredients contemplated for use in the present invention are antacids, H 2 -antagonists, and analgesics.
- antacid dosages can be prepared using the ingredients calcium carbonate alone or in combination with magnesium hydroxide, and/or aluminum hydroxide.
- antacids can be used in combination with H 2 -antagonists.
- Analgesics include aspirin, acetaminophen, and acetaminophen plus caffeine.
- antadiarrheals such as immodium AD, antihistamines, antitussives, decongestants, vitamins, and breath fresheners.
- anxiolytics such as Xanax; antipsychotics such as clozaril and Haldol; non-steroidal anti-inflammatories (NSAID's) such as Voltaren and Lodine; antihistamines such as Seldane, Hismanal, Relafen, and Tavist; antiemetics such as Kytril and Cesamet; bronchodilators such as Bentolin, Proventil; antidepressants such as Prozac, Zoloft, and Paxil; antimigraines such as Imigran, ACE-inhibitors such as Vasotec, Capoten and Zestril; Anti-Alzheimers agents, such as Nicergoline; and Ca H -Antagonists such as Pro
- H 2 -antagonists which are contemplated for use in the present invention include cimetidine, ranitidine hydrochloride, famotidine, nizatidine, ebrotidine, mifentidine, roxatidine, pisatidine and aceroxatidine.
- fragrances are fragrances, dyes, sweeteners both artificial and natural, and other additives.
- fillers may be used to increase the bulk of the tablet.
- Some of the commonly used fillers are calcium sulfate, both di- and tri basic, starch, calcium carbonate, microcrystalline cellulose, modified starches, lactose, sucrose, mannitol, and sorbitol.
- Binders which contributes to the ease of formation and general quality of the tablet. Binders include starches, pregelatinize starches, gelatin, polyvinylpyrrolidone, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, and polyvinylalcohols.
- Lubricants can also be used to aid in tamping and compacting.
- Lubricants can include, but are not limited to, the following: magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene, monostearate, talc, polyethyleneglycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate and light mineral oil.
- disintegrants can be used to enhance the dispersibility of the compressed tablet in an aqueous environment.
- the dispersants can include starch, alginic acid, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicate, and microcrystalline cellulose. In view of the highly dissoluble nature of the product of the present invention, there is little need for disintegrants.
- glidants which adhere to the cohesive material in order to enhance flow properties by reducing interparticle friction.
- Glidants which can be used include starch, talc, magnesium and calcium stearate, zinc stearate, dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, and silica aerogels.
- dispersion enhancers can be used to enhance the breakability of the compressed tablet in an aqueous environment.
- the dispersants can include starch, alginic acid, polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicate, and microcrystalline cellulose as high HLB emulsifier surfactants. In view of the ease with which the product of the present invention disintegrates, there is little need for disintegrants.
- Color additives useful in preparing tablets include food, drug and cosmetics (FD&C) colors, drug and cosmetic (D&C) colors, or external drug and cosmetic (Ext. D&C) colors. These colors are dyes, their corresponding lakes, and certain natural and derived colorants. Lakes are dyes absorbed on aluminum hydroxide.
- the present invention is particularly useful in preparing antacid tablets.
- Antacids are conveniently provided in chewable tablet form to provide a convenient method of delivering antacid to the consumer.
- the chewable form provides an advantage in that the tablet is broken up into granules during chewing and mixed with saliva before swallowing. This renders the tablet antacid formulation a suspension.
- One of the disadvantages of prior art antacid tablets is that the mass of ingredients residing in the mouth during and after chewing have objectional texture and taste.
- the present invention overcomes these disadvantages because the ingredients virtually explode into dissolution. The texture is also significantly enhanced and the residence time is substantially reduced.
- Active antacid ingredients include, but are not limited to, the following: aluminum hydroxide, dihydroxyaluminum aminoacetate, aminoacetic acid, aluminum phosphate, dihydroxyaluminum sodium carbonate, bicarbonate, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium carbonate, calcium phosphate, citrate ion (acid or salt), amino acetic acid, hydrate magnesium aluminate sulfate, magaldrate, magnesium aluminosilicate, magnesium carbonate, magnesium glycinate, magnesium hydroxide, magnesium oxide, magnesium oxide, magnesium trisilicate, milk solids, aluminum mono-ordibasic calcium phosphate, tricalcium phosphate, potassium bicarbonate, sodium tartrate, sodium bicarbonate, magnesium aluminosilicates, tartaric acids and salts.
- Molding is used herein to mean associating uncured (i.e., uncrystallized) shearform matrix material closely enough to provide bridging between crystallized matrix material upon curing. Generally, this requires force sufficient to provide intimate contact of fibers prior to curing, followed by crystallizing to form a bound continuous crystalline structure throughout the tablet. Unlike conventional tabletting which relies primarily on compression to provide the structure, the present process utilizes the curing process to aid in forming the end product. Consequently, mild compression forces can be used to mold the product. In a preferred embodiment, the compression required to mold uncured matrix material is referred to as "tamping.”
- Tamping means compressing with force less than that required in compression tabletting, which is generally regarding as being on the order of thousands of pounds per square inch (psi).
- the maximum pressure used in the present invention is only 500 psi, but in most cases will never exceed about 250 psi, and, in the most preferred embodiments, not more than 80 psi (e.g., 40 psi to 80 psi). These lower pressures are called tamping.
- the product of the present invention should be compressed in an uncured condition to a density of not greater than about 1.20, preferably not greater than 0.8, and, most preferably, not greater than 0.65.
- the present invention requires extremely low pressures for molding, it is possible to mold directly in plastic product wells which can be used as packaging for sales. Consequently, the present invention includes the concept of molding uncured matrix materials clearly in product wells such as plastic blister package depressions.
- the present inventor requires compacting the combination resulting from "combining" the controllable release delivery system and the shearform matrix.
- “Compacting” in the present invention means to press into a comestible unit, e.g., a tablet, at a pressure generally greater than about 500 psi, but not necessarily as great as normal tabletting pressure, which are on the order of magnitude of thousands of psi (i.e., at least about 1000 psi).
- polydextrose especially, Poly DexTM brand polydextrose provided by A. E. Stanley & Co.
- compaction pressure as low as 50 psi has been found to be effective.
- the micro-particulate medium being compacted includes shearform matrix which has been at least partially crystallized.
- the combination of shearform matrix and the additive must be provided as flavorable, compactible micro-particulates.
- the micro-particulates are agglomerates of a sort which include the ingredients of the mixture, but which are relatively low density.
- the "micro-particulates" of the present invention are capable of withstanding relatively high compaction force without experiencing an increase in density. The micro-particulates can then be compacted under relatively high compaction force to form a low density dosage unit having high structural integrity, strength and excellent appearance.
- Micro-particulates are preferably formed by combining the mixture with a crystallization/binding promoter such as ethanol (preferably 200 proof), polyvinylpyrrolidone, a combination thereof, as well as other agents which enhance the formation of micro-particulates without increasing the density of the mixture.
- a crystallization/binding promoter such as ethanol (preferably 200 proof), polyvinylpyrrolidone, a combination thereof, as well as other agents which enhance the formation of micro-particulates without increasing the density of the mixture.
- micro-particulates resulting from the above step can then be compacted, e.g., 6-8 SCUs (Strong Cobb Units), whereby a structurally strong tablet can be formed which has excellent appearance and can be handled without deterioration of the surface or structure.
- 6-8 SCUs Strong Cobb Units
- Curing means binding and crystallizing the matrix material substantially simultaneously. Curing is performed by subjecting product to heat and moisture sufficient to provide controlled crystallization. Controlled crystallization occurs when points of contact of uncured matrix material become points of crystalline growth and crystallization of the material proceeds to provide crystalline structures. Binding occurs at the points of contact, and the simultaneous crystalline growth is such as to maintain structural integrity.
- the "curing" process of the present invention involves a transformation from amorphous to crystalline state.
- the transformation must take place while the amorphous shearform matrix remains bound together.
- the mixture of shearform matrix and active Prior to curing, the mixture of shearform matrix and active are maintained at temperature and humidity below the glass transition temperature of the shearform matrix material.
- Conditions suitable for curing can include ambient conditions of heat and moisture or modified ambient conditions. For example, it has been found that curing can be conducted at a temperature of 0°-90° C. at a relative humidity of 25-90%. In one case, it has been found that curing will take place within 15 minutes at 40° C. and 85% r.h. In other cases, optimum temperature range has ben found to be at 20°-50° C. Microwave energy can be used to controlledly accelerate curing.
- the crystallization is effected in an environment wherein the tabletted material cures to a water content of less than 5% by weight, and preferably less than 1% by weight based on the weight of the tablet.
- the curing environment e.g., chamber or room, is maintained at a relative humidity which permits water pickup no greater than 5%, and preferably less than 1%.
- Products prepared in accordance with the present invention have been found to have densities of from about 0.20 gm/cc 2 to about 0.90 gm/cc 2 , and some preferred embodiments have densities of from about 0.40 gm/cc 2 to about 0.65 gm/cc 2 .
- binding aid or agent Another ingredient which can be included in the shearform matrix is a binding aid or agent.
- a binding agent is used to assist in the molding step and, in some cases, contributes to the dissolution capabilities of the finished product.
- Binding agents useful herein include low-glass-transition materials. Some agents found useful include, but are not limited to, sorbitol, mannitol, lactose, etc. The binding agents are flash flow processed with the carrier. Binding agents also aid in holding the matrix material in place for curing. In some cases portions of the binder becomes part of the matrix material.
- one method of measuring the results of the present invention is the ability to make a low density product.
- the micro-particulates are capable of being subjected to high-pressure without reducing the density of the resulting product. Accordingly, the product prepared in accordance with the present invention even after high-pressure-compaction will still remain below 1.2 grams per cubic centimeter (gr./cc), and preferably below 0.8 gr./cc.
- the pressure required to prepare tablets in accordance with the present invention exceed those generally required in the first embodiment described herein, but are less than those previously required with normal tabletting procedures (albeit some embodiments require no greater compaction pressure than that set forth in U.S. application Ser. No. 08/259,258).
- the increase pressure which can be used to form tablets in accordance with the present invention the strength of the product is increased, and the hardness of the surface is also increased. This results in a confection dosage unit which is able to be handled manually and machine processed without degradation of the surface or structural integrity.
- Micro-particulates retain their individual integrity and lines of disintegration are provided throughout the resulting unit. Moreover, since the mass can be subjected to relatively high-pressure-compaction, the surface of the resulting dosage unit is smooth, and the strength of the tablet is relatively high. Therefore, the resulting units can be easily handled without deterioration of the surface appearance or destruction of the comestible units.
- the material preferably contains up to 5% water, and most preferably up to 1% water.
- the water can be provided by water contained in the ingredients such as that carried in the sugars or binders. Water can also be provided in small amounts in the alcohol, such as in 200 proof alcohol which absorbs moisture rapidly and generally contains small amounts of moisture, e.g., up to 1% by weight. The additional moisture can be provided by ambient surroundings such as the humidity in the air.
- the present invention has been found to be well suited for preparation of antacid tablets and tablets in which antacids are used as an ingredient to ameliorate the acid conditions in the body in order to assist drugs which do not tolerate acidic conditions.
- antacids themselves, the instantaneous dispersion of the tablet in the mouth prevents the residual chalky taste of a conventional antacid tablet.
- ingredients which do not tolerate acidic conditions it is desirable to include the antacids plus the "acid-sensitive" pharmaceutical in a dosage unit prepared according to the invention.
- didanosine is an antiviral agent which does not tolerate an acidic environment well.
- the present invention includes the combination of an "acid-sensitive" ingredient and an antacid in a dosage unit.
- the shearform matrix material used in the following examples is an amorphous sugar.
- Amorphous sugar as used herein means a sugar stock which contains a high percentage of amorphism, i.e., greater than 50% by weight, and preferably greater than 70% by weight of the sugar stock is amorphous.
- a controlled release system was prepared in accordance with the present invention by preparing a shearform matrix using a combination of 49.75% sucrose, 0.025% Tween 80 as a surfactant, 40% CantabTM (a crystalline form of a high D.E., Dextrose Equivalent, Corn Syrup product of Penwest Foods Co., Cedar Rapids, Iowa), and 10% D-Xylose.
- the shearform matrix was collected and comminuted to a small consistent size and stored in an airtight container and subsequently formulated for tabletting.
- the tablet formulation was prepared with 60% floss as set forth above, 37% Contact brand cold medicine, 0.55% Aspartame, 0.5% coloring, 1% Comprital HD5 (a Glycerol Polyethylene Glycol Behenate product of Gattefosse Westwood, N.J.), and 0.50% Syloid 244 FP flow agent. The combination was blended in a manner which ensured the drug was substantially homogenously mixed with the other ingredients.
- Comprital HD5 a Glycerol Polyethylene Glycol Behenate product of Gattefosse Westwood, N.J.
- Syloid 244 FP flow agent a Glycerol Polyethylene Glycol Behenate product of Gattefosse Westwood, N.J.
- the combination was subsequently weighed into 0.7 gram samples and loaded into a press and tabletted by tamping at a 40 pound per square inch pressure for approximately five seconds.
- the resulting tablets had a very uniform and attractive surface, and maintained good physical integrity.
- the tablets were sealed in a blister pack. Tablets crystallized in the packaging over a 24 hour period.
- the tablets produced by the process set forth above were rapidly dispersable in the oral cavity.
- the drug was also rapidly dispersed and it is believed that the process could be easily adapted to existing commercial drug tabletting facilities.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Mechanical Engineering (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/698,907 US5851552A (en) | 1994-06-14 | 1996-08-16 | Delivery of controlled-release system(s) |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25949694A | 1994-06-14 | 1994-06-14 | |
US08/259,258 US5895664A (en) | 1993-09-10 | 1994-06-14 | Process for forming quickly dispersing comestible unit and product therefrom |
US08/334,729 US5567439A (en) | 1994-06-14 | 1994-11-04 | Delivery of controlled-release systems(s) |
US08/698,907 US5851552A (en) | 1994-06-14 | 1996-08-16 | Delivery of controlled-release system(s) |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/334,729 Division US5567439A (en) | 1994-06-14 | 1994-11-04 | Delivery of controlled-release systems(s) |
Publications (1)
Publication Number | Publication Date |
---|---|
US5851552A true US5851552A (en) | 1998-12-22 |
Family
ID=23308558
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/334,729 Expired - Fee Related US5567439A (en) | 1994-06-14 | 1994-11-04 | Delivery of controlled-release systems(s) |
US08/698,922 Expired - Fee Related US5853762A (en) | 1994-06-14 | 1996-08-16 | Delivery of controlled-release system(s) |
US08/698,907 Expired - Lifetime US5851552A (en) | 1994-06-14 | 1996-08-16 | Delivery of controlled-release system(s) |
US08/698,906 Expired - Fee Related US5733577A (en) | 1994-06-14 | 1996-08-16 | Delivery of controlled-release system (s) |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/334,729 Expired - Fee Related US5567439A (en) | 1994-06-14 | 1994-11-04 | Delivery of controlled-release systems(s) |
US08/698,922 Expired - Fee Related US5853762A (en) | 1994-06-14 | 1996-08-16 | Delivery of controlled-release system(s) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/698,906 Expired - Fee Related US5733577A (en) | 1994-06-14 | 1996-08-16 | Delivery of controlled-release system (s) |
Country Status (4)
Country | Link |
---|---|
US (4) | US5567439A (en) |
EP (1) | EP0711547A1 (en) |
JP (1) | JPH08301751A (en) |
CA (1) | CA2161752A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020102336A1 (en) * | 2000-11-29 | 2002-08-01 | Mann Douglas G. | Method of stabilizing fruit-concentrate powders |
US20030108602A1 (en) * | 2000-05-19 | 2003-06-12 | Yamanouchi Pharma Technologies, Inc. | Tablets and methods for modified release of hydrophilic and other active agents |
US6887926B1 (en) | 2001-11-16 | 2005-05-03 | Oatey Co. | Bonding compositions for chlorinated polymers and methods of using the same |
WO2007102150A2 (en) * | 2006-03-09 | 2007-09-13 | Erez Sason | Method and device for flowers and plants |
US20100326454A1 (en) * | 2009-06-30 | 2010-12-30 | Fuisz Richard C | Smokeless Tobacco Product |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US6020002A (en) * | 1994-06-14 | 2000-02-01 | Fuisz Technologies Ltd. | Delivery of controlled-release system(s) |
US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US6726928B2 (en) | 1994-10-28 | 2004-04-27 | R.P. Scherer Technologies, Inc. | Process for preparing solid dosage forms for unpalatable pharmaceuticals |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
CN1090935C (en) * | 1995-02-28 | 2002-09-18 | 阿温蒂斯药物公司 | Pharmaceutical composition for piperidinoalkanol compounds |
US20030109503A1 (en) * | 1995-06-06 | 2003-06-12 | Smithkline Beecham P.L.C. | Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics |
US6964771B1 (en) * | 1995-06-07 | 2005-11-15 | Elan Drug Delivery Limited | Method for stably incorporating substances within dry, foamed glass matrices |
JP3501289B2 (en) * | 1995-09-07 | 2004-03-02 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Pharmaceutical prescription |
US5637326A (en) * | 1995-12-04 | 1997-06-10 | Fuisz Technologies Ltd. | Apparatus for making chopped amorphous fibers with an air transport system |
WO1997038679A2 (en) * | 1996-04-16 | 1997-10-23 | Novartis Consumer Health S.A. | Fast disintegrating oral dosage form |
JP3555640B2 (en) * | 1996-05-10 | 2004-08-18 | ライオン株式会社 | Multicapsulated microcapsules containing natural carotenoids, tablets, food and pharmaceutical compounds |
US6468782B1 (en) * | 1996-12-05 | 2002-10-22 | Quadrant Healthcare (Uk) Limited | Methods of preserving prokaryotic cells and compositions obtained thereby |
GB9702799D0 (en) * | 1997-02-12 | 1997-04-02 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms |
US20030124187A1 (en) * | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
US5879699A (en) * | 1997-06-03 | 1999-03-09 | Lerner; Julie Beth Green | Medication dispensing system |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
NZ501248A (en) * | 1997-08-26 | 2001-06-29 | Aventis Pharma Inc | Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US8765177B2 (en) | 1997-09-12 | 2014-07-01 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
IN186245B (en) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
EP1030560B1 (en) | 1997-10-09 | 2007-09-26 | Emory University | Method and devices for transdermal delivery of lithium |
GB9802088D0 (en) * | 1998-01-30 | 1998-03-25 | Scherer Ltd R P | Pharmaceutical products |
CN1160079C (en) * | 1998-03-11 | 2004-08-04 | 格勒兰制药株式会社 | Bubbling enteric coated preparations |
DE19814392A1 (en) * | 1998-03-31 | 1999-10-07 | Hermes Fabrik Pharm Praeparate | Effervescent tablet containing calcium with an antihistamine as active ingredient |
US6171615B1 (en) | 1998-07-06 | 2001-01-09 | Gattefoss{acute over (e)} | Sustained release theophylline formulations, excipient systems and methods of production |
IT1301966B1 (en) | 1998-07-30 | 2000-07-20 | Zambon Spa | PHARMACEUTICAL COMPOSITIONS WITH ANALGESIC ACTIVITY |
US6117452A (en) * | 1998-08-12 | 2000-09-12 | Fuisz Technologies Ltd. | Fatty ester combinations |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
AU6428099A (en) * | 1998-10-16 | 2000-05-08 | Fuisz Technologies Ltd. | Dry deodorizing composition for oral administration |
FR2785539B1 (en) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | PARTICLES COATED WITH GRANULATED CRYSTALLINE IBUPROFENE |
FR2785538B1 (en) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | PERFECTED QUICK DELIVERY TABLET |
US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
US6878386B1 (en) | 1999-04-13 | 2005-04-12 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
US6294199B1 (en) * | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
US7250176B1 (en) * | 1999-04-13 | 2007-07-31 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection |
WO2000062759A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Dry, mouldable drug formulation |
DE19918325A1 (en) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives |
GB9910505D0 (en) | 1999-05-06 | 1999-07-07 | Electrosols Ltd | A method and apparatus for manufacturing consumable tablets |
US20050079214A1 (en) * | 1999-09-01 | 2005-04-14 | John Cooker | Oral delivery system and method for making same |
US20040101540A1 (en) * | 1999-09-01 | 2004-05-27 | John Cooker | Oral delivery system and method for making same |
US6656501B1 (en) | 1999-09-01 | 2003-12-02 | John T. Cooker | Oral delivery system and method for making same |
US6541025B1 (en) * | 1999-12-30 | 2003-04-01 | Shear/Kershman Laboratories, Inc. | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
AU2004202461B2 (en) * | 2000-01-28 | 2007-11-22 | Smithkline Beecham Corporation | Electrospun pharmaceutical compositions |
PL356924A1 (en) | 2000-01-28 | 2004-07-12 | Smithkline Beecham Corporation | Electrospun pharmaceutical compositions |
DK1280520T4 (en) | 2000-05-10 | 2018-06-25 | Novartis Ag | Phospholipid based powders for drug delivery |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
AU2001275043A1 (en) * | 2000-05-31 | 2001-12-11 | Drugtech Corporation | Mineral supplement |
EP1313425B1 (en) * | 2000-07-14 | 2007-03-07 | Novo Nordisk A/S | Method of moulding a pharmaceutical composition in a packaging material |
WO2002015884A2 (en) * | 2000-08-18 | 2002-02-28 | Pharmacia Corporation | Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
US6756057B2 (en) | 2000-10-12 | 2004-06-29 | Beecham Pharmaceuticals (Pte) Limited | Amoxicillin and potassium clavulanate dosage form |
AU2001292185A1 (en) | 2000-10-12 | 2002-04-22 | Beecham Pharmaceuticals (Pte) Limited | Formulation containing amoxicillin |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
JP2004520389A (en) * | 2001-02-08 | 2004-07-08 | ファルマシア・コーポレーション | Early-effect drugs for the treatment of sexual dysfunction |
WO2002076425A2 (en) * | 2001-03-22 | 2002-10-03 | Battelle (Memorial Institute) | Manufacturing dissolvable dosage forms |
US7291352B2 (en) | 2001-10-03 | 2007-11-06 | Herbalscience Llc | Methods and compositions for oral delivery of Areca and mate' or theobromine |
US20050069596A1 (en) * | 2001-10-03 | 2005-03-31 | Gow Robert T. | Compositions and methods comprising kava and anti-anxiety compounds |
US7029707B2 (en) * | 2001-10-03 | 2006-04-18 | Herbalscience, Llc | Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same |
US20050053678A1 (en) * | 2001-10-03 | 2005-03-10 | Gow Robert T. | Methods and compositions for betel nut chewing gum |
DK1443912T3 (en) | 2001-10-12 | 2008-01-21 | Elan Pharma Int Ltd | Compositions with a combination of immediate and controlled release properties |
US8454997B2 (en) * | 2001-12-18 | 2013-06-04 | Novo Nordisk A/S | Solid dose micro implant |
EP1458360B1 (en) | 2001-12-19 | 2011-05-11 | Novartis AG | Pulmonary delivery of aminoglycosides |
EP1941878A1 (en) | 2002-01-10 | 2008-07-09 | Biovail Laboratories International Srl | Sedative non-benzodiazepine formulations |
EP1490031A1 (en) * | 2002-03-07 | 2004-12-29 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
US20030017208A1 (en) * | 2002-07-19 | 2003-01-23 | Francis Ignatious | Electrospun pharmaceutical compositions |
TW200410714A (en) * | 2002-08-07 | 2004-07-01 | Smithkline Beecham Corp | Electrospun amorphous pharmaceutical compositions |
US20050037025A1 (en) * | 2002-10-03 | 2005-02-17 | Gow Robert T. | Methods and compositions comprising kava and mate' or theobromine |
CA2500919A1 (en) * | 2002-10-04 | 2004-04-22 | Pharmacia Corporation | Compositions and methods for treating sexual dysfunction |
WO2004043440A1 (en) * | 2002-11-12 | 2004-05-27 | Elan Pharma International Ltd. | Fast-disintegrating solid dosage forms being not friable and comprising pullulan |
EP1601669B1 (en) | 2003-03-07 | 2008-12-24 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
ES2311806T3 (en) * | 2003-03-07 | 2009-02-16 | Schering Corporation | AZETIDINONA COMPOSITE SUBSTITUTED, FORNULATIONS AND USES OF THE SAME FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA. |
PT1575565E (en) * | 2003-08-08 | 2010-03-03 | Biovail Lab Int Srl | Modified-release tablet of bupropion hydrochloride |
US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
US7294353B2 (en) * | 2003-10-24 | 2007-11-13 | Herbalscience, Llc | Methods and compositions comprising ilex |
US7279184B2 (en) * | 2003-10-24 | 2007-10-09 | Herbalscience, Llc | Methods and compositions comprising Ilex |
WO2005044006A1 (en) * | 2003-11-05 | 2005-05-19 | Battelle Memorial Institute | Quick dissolving agrochemical products |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
CN1889932A (en) * | 2003-12-04 | 2007-01-03 | 辉瑞产品公司 | Method of making pharmaceutical multiparticulates |
CA2547597A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
MXPA06005913A (en) * | 2003-12-04 | 2006-06-27 | Pfizer Prod Inc | Azithromycin multiparticulate dosage forms by liquid-based processes. |
CN1889931A (en) * | 2003-12-04 | 2007-01-03 | 辉瑞产品公司 | Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
EP1689368B1 (en) * | 2003-12-04 | 2016-09-28 | Bend Research, Inc | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions |
US20050136112A1 (en) * | 2003-12-19 | 2005-06-23 | Pediamed Pharmaceuticals, Inc. | Oral medicament delivery system |
US20050244493A1 (en) * | 2004-04-30 | 2005-11-03 | Withiam Michael C | Rapidly disintegrating tablets comprising calcium carbonate |
RU2408368C2 (en) | 2005-06-27 | 2011-01-10 | Биовэйл Лэборэториз Интернэшнл С.Р.Л. | Modified release bupropion salt preparations |
AU2006269944A1 (en) * | 2005-07-19 | 2007-01-25 | Inverseon, Inc. | Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases |
EP2388263A1 (en) | 2005-08-04 | 2011-11-23 | Sirtris Pharmaceuticals, Inc. | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators |
US9877921B2 (en) | 2005-09-09 | 2018-01-30 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
US20070059361A1 (en) * | 2005-09-09 | 2007-03-15 | University Of Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
WO2013059629A1 (en) | 2011-10-21 | 2013-04-25 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
US20160045457A1 (en) | 2005-09-09 | 2016-02-18 | Ousama Rachid | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine |
US20070141147A1 (en) * | 2005-12-21 | 2007-06-21 | Auriga Laboratories, Inc. | Sequential release pharmaceutical formulations |
US20070243248A1 (en) * | 2006-04-14 | 2007-10-18 | Cherukuri S Rao | Rapidly disintegrating solid oral dosage form of liquid dispersions |
WO2007130373A2 (en) * | 2006-05-01 | 2007-11-15 | Capricorn Pharma, Inc. | Novel triptan formulations and methods for making them |
US20070293582A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
US20070293580A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies |
US20080057122A1 (en) * | 2006-08-31 | 2008-03-06 | Aaipharma Inc. | Acetaminophen pharmaceutical compositions |
US20080187628A1 (en) * | 2007-02-02 | 2008-08-07 | Champion Melinda L | Water-Soluble, Quick-Dissolve Flavor Tablets |
US20080248141A1 (en) * | 2007-04-05 | 2008-10-09 | Marvin Heuer | Composition for a feeling of relaxation |
KR101109633B1 (en) * | 2007-08-03 | 2012-01-31 | 제이더블유중외제약 주식회사 | Composition for manufacturing orally disintegrating dosage forms, for protecting the coating of active substance |
US20090246276A1 (en) | 2008-01-28 | 2009-10-01 | Graham Jackson | Pharmaceutical Compositions |
CA2767335C (en) * | 2009-07-14 | 2013-09-24 | Hill's Pet Nutrition, Inc. | Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof |
PL2475352T5 (en) * | 2009-09-07 | 2019-02-28 | Epitech Group S.P.A. | Composition containing ultra-micronized palmitoyl - ethanolamide |
PL2519230T3 (en) | 2009-12-31 | 2019-05-31 | Marius Pharmaceuticals Llc | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
EP2540318B1 (en) * | 2010-02-22 | 2018-10-24 | Daiichi Sankyo Company, Limited | Sustained-release solid preparation for oral use |
US8397945B2 (en) | 2010-02-23 | 2013-03-19 | R.J. Reynolds Tobacco Company | Dispensing container |
US20120322884A1 (en) | 2010-03-01 | 2012-12-20 | University Of Manitoba | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
MX2013002430A (en) | 2010-09-01 | 2013-07-22 | Arena Pharm Inc | Fast-dissolve dosage forms of 5-ht2c agonists. |
MY166034A (en) | 2010-12-22 | 2018-05-21 | Purdue Pharma Lp | Encased tamper resistant controlled release dosage forms |
JP5638151B2 (en) | 2010-12-23 | 2014-12-10 | パーデュー、ファーマ、リミテッド、パートナーシップ | Tamper resistant solid oral dosage form |
PL2688556T3 (en) * | 2011-03-25 | 2015-10-30 | Purdue Pharma Lp | Controlled release pharmaceutical dosage forms |
WO2013149258A2 (en) | 2012-03-30 | 2013-10-03 | Charles Drew University of Medicine and Science | Compositions and methods for treating or preventing metabolic syndrome disorders |
CA2876883C (en) | 2012-06-15 | 2022-11-01 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
KR102127625B1 (en) | 2012-09-03 | 2020-06-29 | 다이이찌 산쿄 가부시키가이샤 | Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition |
US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
WO2014143127A1 (en) | 2013-03-15 | 2014-09-18 | Differential Drug Development Associates Llc | Emulsion formulations |
EP2976072B9 (en) | 2013-03-22 | 2021-10-13 | Nova Southeastern University | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine |
US10716783B2 (en) | 2013-12-12 | 2020-07-21 | Cornell University | Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom |
RU2747316C2 (en) | 2016-03-01 | 2021-05-04 | Асцендис Фарма Боун Дизизис А/С | Rtn prodrugs |
EP4275677A3 (en) | 2016-09-29 | 2024-01-10 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release pth compound |
JP7085535B2 (en) | 2016-09-29 | 2022-06-16 | アセンディス ファーマ ボーン ディジージズ エー/エス | PTH compounds with a small peak-to-trough ratio |
KR102182559B1 (en) | 2017-09-08 | 2020-11-24 | 인시그니스 쎄라퓨틱스, 인코포레이티드 | How to use difibephrine |
AU2018360383A1 (en) | 2017-11-02 | 2020-05-21 | Natureceuticals Sdn. Bhd. | Extract of orthosiphon stamineus, formulations, and uses thereof |
US11213484B2 (en) | 2019-03-01 | 2022-01-04 | Insignis Therapeutics, Inc. | Dipivefrin orally disintegrating tablet formulations |
Citations (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2826169A (en) * | 1954-01-21 | 1958-03-11 | Veen Harry H Le | Reflective heat insulating coating for animals |
US2918404A (en) * | 1956-07-30 | 1959-12-22 | Ortho Pharma Corp | Solid compressed amino acid spermicidal vehicle |
US3019745A (en) * | 1960-10-03 | 1962-02-06 | Bois Albert Du | Sugar spinning machine |
US3036532A (en) * | 1960-06-28 | 1962-05-29 | Bowe John | Cotton candy machine with product of alternating colors |
US3067743A (en) * | 1958-11-12 | 1962-12-11 | Alginate Ind Ltd | Alginic compounds |
US3070045A (en) * | 1961-04-24 | 1962-12-25 | Bowe John | Machine for spinning sugar |
US3073262A (en) * | 1961-08-16 | 1963-01-15 | Bowe John | Spinner head for candy cotton machine |
US3095258A (en) * | 1962-06-22 | 1963-06-25 | Du Pont | Melt spinning process for producing hollow-core filament |
US3118396A (en) * | 1964-01-21 | Machine for making candy | ||
US3131428A (en) * | 1958-12-19 | 1964-05-05 | Celanese Corp | Spinneret and spinning method |
US3308221A (en) * | 1963-05-14 | 1967-03-07 | Allied Chem | Melt spinning of modified cross section yarn |
US3324061A (en) * | 1962-01-15 | 1967-06-06 | Minnesota Mining & Mfg | Preparing aqueous solutions of polypyrrolidone |
US3482998A (en) * | 1966-02-17 | 1969-12-09 | Gen Mills Inc | Process for preparing ground meat composition |
CH489211A (en) * | 1968-07-09 | 1970-04-30 | Nestle Sa | Process for manufacturing a heat-resistant chocolate |
US3523889A (en) * | 1968-11-26 | 1970-08-11 | American Sugar | Method and apparatus for separating liquids from solids |
US3557717A (en) * | 1968-05-17 | 1971-01-26 | Gen Mills Inc | Process for making candy floss |
US3595675A (en) * | 1966-11-21 | 1971-07-27 | Gen Mills Inc | Gelatin composition |
US3615671A (en) * | 1968-04-19 | 1971-10-26 | Gen Foods Corp | Dry food products in spun filaments and method of making same |
US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
CH519858A (en) * | 1971-05-04 | 1972-03-15 | Interfood S A | Heat-resistant sweets - contg encapsulated fats and cocoa materials |
US3676148A (en) * | 1970-05-13 | 1972-07-11 | Scm Corp | Edible comestibles and process for making same |
US3686000A (en) * | 1971-01-11 | 1972-08-22 | Gen Foods Corp | Moisture resistant sugar filaments |
US3723134A (en) * | 1968-05-17 | 1973-03-27 | Gen Mills Inc | Process for making candy floss |
US3762846A (en) * | 1968-05-17 | 1973-10-02 | Gen Mills Inc | Process and apparatus for making candy floss |
US3766165A (en) * | 1966-08-17 | 1973-10-16 | Pfizer | Polysaccharides and their preparation |
US3856443A (en) * | 1973-08-06 | 1974-12-24 | Gen Properties Anstalt | Apparatus for producing candyfloss |
US3875300A (en) * | 1972-12-18 | 1975-04-01 | Ortho Pharma Corp | Composition for sustained release of a medicament and method of using same |
US3876794A (en) * | 1972-12-20 | 1975-04-08 | Pfizer | Dietetic foods |
US3925525A (en) * | 1973-08-10 | 1975-12-09 | Celanese Corp | Spinning method |
US3930043A (en) * | 1973-07-19 | 1975-12-30 | Tec Pak Corp | Method for making cotton candy |
US3951821A (en) * | 1972-07-14 | 1976-04-20 | The Dow Chemical Company | Disintegrating agent for tablets |
US3967623A (en) * | 1975-06-30 | 1976-07-06 | Johnson & Johnson | Disposable absorbent pad |
US3972725A (en) * | 1974-04-16 | 1976-08-03 | Tate & Lyle Limited | Production of crystalline sugar |
US3981739A (en) * | 1974-08-30 | 1976-09-21 | Amstar Corporation | Continuous crystallization |
US3992265A (en) * | 1975-12-31 | 1976-11-16 | American Cyanamid Company | Antibiotic susceptibility testing |
US4056364A (en) * | 1974-08-30 | 1977-11-01 | Amstar Corporation | Two stage continuous crystallization apparatus with controls |
US4086418A (en) * | 1976-02-27 | 1978-04-25 | International Telephone And Telegraph Corporation | Process for producing a regenerated hollow cellulosic fiber |
US4090920A (en) * | 1976-02-19 | 1978-05-23 | Fisher Scientific Company | Disposable antibiotic susceptability test package |
US4136145A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
US4153512A (en) * | 1976-04-07 | 1979-05-08 | Fisher Scientific Company | Storage stable antibiotic susceptibility test kit and method of testing |
US4159210A (en) * | 1978-06-15 | 1979-06-26 | Amstar Corporation | Maple sugar product and method of preparing and using same |
US4293570A (en) * | 1979-04-02 | 1981-10-06 | Chimicasa Gmbh | Process for the preparation of sweetener containing product |
US4303684A (en) * | 1980-03-17 | 1981-12-01 | General Foods Corporation | Rapidly-soluble sweetener, process for its preparation and beverage mix employing it |
US4338350A (en) * | 1980-10-22 | 1982-07-06 | Amstar Corporation | Crystallized, readily water-dispersible sugar product |
US4348420A (en) * | 1980-08-25 | 1982-09-07 | Nutrisearch Company | Process for binding comminuted meat |
US4362757A (en) * | 1980-10-22 | 1982-12-07 | Amstar Corporation | Crystallized, readily water dispersible sugar product containing heat sensitive, acidic or high invert sugar substances |
US4371516A (en) * | 1976-10-06 | 1983-02-01 | John Wyeth & Brother Limited | Articles for carrying chemicals |
US4376743A (en) * | 1981-06-12 | 1983-03-15 | Fiber Industries, Inc. | Melt spinning process |
US4492685A (en) * | 1979-08-14 | 1985-01-08 | Key Pharmaceuticals, Inc. | Protective skin matrix |
BE900605A (en) * | 1983-10-07 | 1985-01-16 | Lisapharma Spa | PHARMACEUTICAL COMPOSITIONS WITH ANTI-INFLAMMATORY AND / OR ANALGESIC ACTIVITY, NON ULCEROGENIC. |
US4496592A (en) * | 1982-10-05 | 1985-01-29 | Meiji Seika Kaisha, Ltd. | Process for producing chewing gum in the form of composite fibers |
US4500546A (en) * | 1980-10-31 | 1985-02-19 | International Telephone And Telegraph Corporation | Suspensions containing microfibrillated cellulose |
US4511584A (en) * | 1983-05-31 | 1985-04-16 | Scm Corporation | Particulate food acidulant |
US4526525A (en) * | 1983-04-08 | 1985-07-02 | Meiji Seika Kaisha, Ltd. | Fleecy confectionery producing machine |
GB2155934A (en) * | 1984-03-15 | 1985-10-02 | Tate & Lyle Plc | Sugar process |
US4585797A (en) * | 1981-04-13 | 1986-04-29 | Seton Company | Cosmetic and pharmaceutical sheet material containing polypeptides |
US4619833A (en) * | 1984-12-13 | 1986-10-28 | General Foods Inc. | Process for producing a rapidly water-soluble, free-flowing, sugar-free dry beverage mix |
US4772477A (en) * | 1986-10-17 | 1988-09-20 | Balchem Corporation | Meat acidulant |
EP0287488A1 (en) * | 1987-04-07 | 1988-10-19 | Recherche Informatique Et Pharmacie R.I.Ph., Sarl | Medicament, dietary product and hygienic product in the form of a powdery composition obtained by adsorption of the active agents on a rapidly dissolving sugar, and process for the preparation of this composition |
ZA882771B (en) * | 1987-04-20 | 1988-10-21 | C. Fuisz Richard | Rapidly dissoluble medicinal dosage unit and method of manufacture |
US4793782A (en) * | 1986-12-17 | 1988-12-27 | Sells-Floto Inc. | Cotton candy machine |
US4855326A (en) * | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
US4872821A (en) * | 1987-03-23 | 1989-10-10 | Gold Medal Products Co. | Cotton candy machine |
US4873085A (en) * | 1987-04-20 | 1989-10-10 | Fuisz Pharmaceutical Ltd. | Spun fibrous cosmetic and method of use |
US4879108A (en) * | 1985-12-20 | 1989-11-07 | Warner-Lambert Company | Confectionery delivery system for antipyretics |
US4885281A (en) * | 1984-08-22 | 1989-12-05 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Sucralfate suspension |
EP0387950A1 (en) * | 1989-03-13 | 1990-09-19 | Stork Friesland B.V. | Spray drying apparatus; method for preparation of a spray-dried product having a desired bulk density |
ZA899318B (en) * | 1988-12-13 | 1990-09-26 | Fuisz Pharmaceutical Ltd | Dispersed systems and method of manufacture |
US4978537A (en) * | 1989-04-19 | 1990-12-18 | Wm. Wrigley Jr. Company | Gradual release structures for chewing gum |
ZA902139B (en) * | 1989-03-20 | 1990-12-28 | Fuisz Pharmaceutical Ltd | A moderated spun fibrous system and method of manufacture |
US4997856A (en) * | 1987-04-20 | 1991-03-05 | Fuisz Pharmaceutical Ltd. | Method of producing compacted dispersable systems |
US5028632A (en) * | 1987-04-20 | 1991-07-02 | Fuisz Pharmaceutical Ltd. | Taste masked medicated pharmaceutical |
ZA908406B (en) * | 1990-10-19 | 1991-08-28 | Fuisz Pharmaceutical Ltd | Taste masked medicated floss |
WO1991018613A1 (en) * | 1990-06-01 | 1991-12-12 | Research Corporation Technologies, Inc. | Self-emulsifying glasses |
US5073387A (en) * | 1990-01-24 | 1991-12-17 | Lafayette Applied Chemistry, Inc. | Method for preparing reduced calorie foods |
US5082684A (en) * | 1990-02-05 | 1992-01-21 | Pfizer Inc. | Low-calorie fat substitute |
US5082682A (en) * | 1990-11-09 | 1992-01-21 | Fantasy Flavors, Inc. | Nonfat frozen dairy dessert with method and premix therefor |
US5084295A (en) * | 1990-02-02 | 1992-01-28 | The Procter & Gamble Company | Process for making low calorie fat-containing frozen dessert products having smooth, creamy, nongritty mouthfeel |
US5089606A (en) * | 1989-01-24 | 1992-02-18 | Minnesota Mining And Manufacturing Company | Water-insoluble polysaccharide hydrogel foam for medical applications |
US5094872A (en) * | 1989-07-19 | 1992-03-10 | American Maize-Products Company | Method for making a reduced fat product |
US5096492A (en) * | 1987-04-20 | 1992-03-17 | Fuisz Technologies Ltd. | Dispersed systems and method of manufacture |
US5236734A (en) * | 1987-04-20 | 1993-08-17 | Fuisz Technologies Ltd. | Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix |
US5464632A (en) * | 1991-07-22 | 1995-11-07 | Laboratoires Prographarm | Rapidly disintegratable multiparticular tablet |
US5501858A (en) * | 1992-05-12 | 1996-03-26 | Fuisz Technologies Ltd. | Rapidly dispersable compositions containing polydextrose |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US5587172A (en) * | 1993-09-10 | 1996-12-24 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5654003A (en) * | 1992-03-05 | 1997-08-05 | Fuisz Technologies Ltd. | Process and apparatus for making tablets and tablets made therefrom |
US5705183A (en) * | 1994-11-16 | 1998-01-06 | Phillips Company | Cotton candy coated medication and a method for making and administering the same |
US5709876A (en) * | 1991-10-25 | 1998-01-20 | Fuisz Technologies Ltd. | Saccharide-based matrix |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5456932A (en) * | 1987-04-20 | 1995-10-10 | Fuisz Technologies Ltd. | Method of converting a feedstock to a shearform product and product thereof |
US4994242A (en) * | 1988-08-15 | 1991-02-19 | Noram Engineering And Constructors Ltd. | Jet impingement reactor |
DK166792B1 (en) * | 1991-06-18 | 1993-07-19 | Burmeister & Wains Energi | PROCEDURE FOR REMOVING STRAWBERRIES |
PL170554B1 (en) * | 1991-12-17 | 1996-12-31 | Fuisz Technologies Ltd | Method of obtaining an anti-ulcerous composition |
CA2126441C (en) * | 1991-12-30 | 1999-12-21 | David F. Erkoboni | Microcrystalline cellulose spheronization composition |
JP3069458B2 (en) * | 1992-01-29 | 2000-07-24 | 武田薬品工業株式会社 | Orally disintegrating tablet and production method thereof |
US5348758A (en) * | 1992-10-20 | 1994-09-20 | Fuisz Technologies Ltd. | Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material |
US5380473A (en) * | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
DE19509807A1 (en) * | 1995-03-21 | 1996-09-26 | Basf Ag | Process for the preparation of active substance preparations in the form of a solid solution of the active substance in a polymer matrix, and active substance preparations produced using this method |
-
1994
- 1994-11-04 US US08/334,729 patent/US5567439A/en not_active Expired - Fee Related
-
1995
- 1995-10-26 EP EP95650038A patent/EP0711547A1/en not_active Withdrawn
- 1995-10-30 CA CA002161752A patent/CA2161752A1/en not_active Abandoned
- 1995-11-06 JP JP7323426A patent/JPH08301751A/en active Pending
-
1996
- 1996-08-16 US US08/698,922 patent/US5853762A/en not_active Expired - Fee Related
- 1996-08-16 US US08/698,907 patent/US5851552A/en not_active Expired - Lifetime
- 1996-08-16 US US08/698,906 patent/US5733577A/en not_active Expired - Fee Related
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3118396A (en) * | 1964-01-21 | Machine for making candy | ||
US2826169A (en) * | 1954-01-21 | 1958-03-11 | Veen Harry H Le | Reflective heat insulating coating for animals |
US2918404A (en) * | 1956-07-30 | 1959-12-22 | Ortho Pharma Corp | Solid compressed amino acid spermicidal vehicle |
US3067743A (en) * | 1958-11-12 | 1962-12-11 | Alginate Ind Ltd | Alginic compounds |
US3131428A (en) * | 1958-12-19 | 1964-05-05 | Celanese Corp | Spinneret and spinning method |
US3036532A (en) * | 1960-06-28 | 1962-05-29 | Bowe John | Cotton candy machine with product of alternating colors |
US3019745A (en) * | 1960-10-03 | 1962-02-06 | Bois Albert Du | Sugar spinning machine |
US3070045A (en) * | 1961-04-24 | 1962-12-25 | Bowe John | Machine for spinning sugar |
US3073262A (en) * | 1961-08-16 | 1963-01-15 | Bowe John | Spinner head for candy cotton machine |
US3324061A (en) * | 1962-01-15 | 1967-06-06 | Minnesota Mining & Mfg | Preparing aqueous solutions of polypyrrolidone |
US3095258A (en) * | 1962-06-22 | 1963-06-25 | Du Pont | Melt spinning process for producing hollow-core filament |
US3308221A (en) * | 1963-05-14 | 1967-03-07 | Allied Chem | Melt spinning of modified cross section yarn |
US3482998A (en) * | 1966-02-17 | 1969-12-09 | Gen Mills Inc | Process for preparing ground meat composition |
US3766165A (en) * | 1966-08-17 | 1973-10-16 | Pfizer | Polysaccharides and their preparation |
US3595675A (en) * | 1966-11-21 | 1971-07-27 | Gen Mills Inc | Gelatin composition |
US3615671A (en) * | 1968-04-19 | 1971-10-26 | Gen Foods Corp | Dry food products in spun filaments and method of making same |
US3762846A (en) * | 1968-05-17 | 1973-10-02 | Gen Mills Inc | Process and apparatus for making candy floss |
US3723134A (en) * | 1968-05-17 | 1973-03-27 | Gen Mills Inc | Process for making candy floss |
US3557717A (en) * | 1968-05-17 | 1971-01-26 | Gen Mills Inc | Process for making candy floss |
CH489211A (en) * | 1968-07-09 | 1970-04-30 | Nestle Sa | Process for manufacturing a heat-resistant chocolate |
US3523889B1 (en) * | 1968-11-26 | 1987-06-02 | ||
US3523889A (en) * | 1968-11-26 | 1970-08-11 | American Sugar | Method and apparatus for separating liquids from solids |
US3676148A (en) * | 1970-05-13 | 1972-07-11 | Scm Corp | Edible comestibles and process for making same |
US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US3686000A (en) * | 1971-01-11 | 1972-08-22 | Gen Foods Corp | Moisture resistant sugar filaments |
CH519858A (en) * | 1971-05-04 | 1972-03-15 | Interfood S A | Heat-resistant sweets - contg encapsulated fats and cocoa materials |
US3951821A (en) * | 1972-07-14 | 1976-04-20 | The Dow Chemical Company | Disintegrating agent for tablets |
US3875300A (en) * | 1972-12-18 | 1975-04-01 | Ortho Pharma Corp | Composition for sustained release of a medicament and method of using same |
US3876794A (en) * | 1972-12-20 | 1975-04-08 | Pfizer | Dietetic foods |
US3930043A (en) * | 1973-07-19 | 1975-12-30 | Tec Pak Corp | Method for making cotton candy |
US3856443A (en) * | 1973-08-06 | 1974-12-24 | Gen Properties Anstalt | Apparatus for producing candyfloss |
US3925525A (en) * | 1973-08-10 | 1975-12-09 | Celanese Corp | Spinning method |
US3972725A (en) * | 1974-04-16 | 1976-08-03 | Tate & Lyle Limited | Production of crystalline sugar |
US4136145A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
US3981739A (en) * | 1974-08-30 | 1976-09-21 | Amstar Corporation | Continuous crystallization |
US4056364A (en) * | 1974-08-30 | 1977-11-01 | Amstar Corporation | Two stage continuous crystallization apparatus with controls |
US3967623A (en) * | 1975-06-30 | 1976-07-06 | Johnson & Johnson | Disposable absorbent pad |
US3992265A (en) * | 1975-12-31 | 1976-11-16 | American Cyanamid Company | Antibiotic susceptibility testing |
US4090920A (en) * | 1976-02-19 | 1978-05-23 | Fisher Scientific Company | Disposable antibiotic susceptability test package |
US4086418A (en) * | 1976-02-27 | 1978-04-25 | International Telephone And Telegraph Corporation | Process for producing a regenerated hollow cellulosic fiber |
US4153512A (en) * | 1976-04-07 | 1979-05-08 | Fisher Scientific Company | Storage stable antibiotic susceptibility test kit and method of testing |
US4371516A (en) * | 1976-10-06 | 1983-02-01 | John Wyeth & Brother Limited | Articles for carrying chemicals |
US4159210A (en) * | 1978-06-15 | 1979-06-26 | Amstar Corporation | Maple sugar product and method of preparing and using same |
US4293570A (en) * | 1979-04-02 | 1981-10-06 | Chimicasa Gmbh | Process for the preparation of sweetener containing product |
US4492685A (en) * | 1979-08-14 | 1985-01-08 | Key Pharmaceuticals, Inc. | Protective skin matrix |
US4303684A (en) * | 1980-03-17 | 1981-12-01 | General Foods Corporation | Rapidly-soluble sweetener, process for its preparation and beverage mix employing it |
US4348420A (en) * | 1980-08-25 | 1982-09-07 | Nutrisearch Company | Process for binding comminuted meat |
US4338350A (en) * | 1980-10-22 | 1982-07-06 | Amstar Corporation | Crystallized, readily water-dispersible sugar product |
US4362757A (en) * | 1980-10-22 | 1982-12-07 | Amstar Corporation | Crystallized, readily water dispersible sugar product containing heat sensitive, acidic or high invert sugar substances |
US4500546A (en) * | 1980-10-31 | 1985-02-19 | International Telephone And Telegraph Corporation | Suspensions containing microfibrillated cellulose |
US4585797A (en) * | 1981-04-13 | 1986-04-29 | Seton Company | Cosmetic and pharmaceutical sheet material containing polypeptides |
US4376743A (en) * | 1981-06-12 | 1983-03-15 | Fiber Industries, Inc. | Melt spinning process |
US4496592A (en) * | 1982-10-05 | 1985-01-29 | Meiji Seika Kaisha, Ltd. | Process for producing chewing gum in the form of composite fibers |
US4526525A (en) * | 1983-04-08 | 1985-07-02 | Meiji Seika Kaisha, Ltd. | Fleecy confectionery producing machine |
US4511584A (en) * | 1983-05-31 | 1985-04-16 | Scm Corporation | Particulate food acidulant |
BE900605A (en) * | 1983-10-07 | 1985-01-16 | Lisapharma Spa | PHARMACEUTICAL COMPOSITIONS WITH ANTI-INFLAMMATORY AND / OR ANALGESIC ACTIVITY, NON ULCEROGENIC. |
GB2155934A (en) * | 1984-03-15 | 1985-10-02 | Tate & Lyle Plc | Sugar process |
US4885281A (en) * | 1984-08-22 | 1989-12-05 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Sucralfate suspension |
US4619833A (en) * | 1984-12-13 | 1986-10-28 | General Foods Inc. | Process for producing a rapidly water-soluble, free-flowing, sugar-free dry beverage mix |
US4879108A (en) * | 1985-12-20 | 1989-11-07 | Warner-Lambert Company | Confectionery delivery system for antipyretics |
US4772477A (en) * | 1986-10-17 | 1988-09-20 | Balchem Corporation | Meat acidulant |
US4793782A (en) * | 1986-12-17 | 1988-12-27 | Sells-Floto Inc. | Cotton candy machine |
US4872821A (en) * | 1987-03-23 | 1989-10-10 | Gold Medal Products Co. | Cotton candy machine |
EP0287488A1 (en) * | 1987-04-07 | 1988-10-19 | Recherche Informatique Et Pharmacie R.I.Ph., Sarl | Medicament, dietary product and hygienic product in the form of a powdery composition obtained by adsorption of the active agents on a rapidly dissolving sugar, and process for the preparation of this composition |
AU609135B2 (en) * | 1987-04-20 | 1991-04-26 | Fuisz Pharmaceutical Ltd. | A spun fibrous cosmetic and method of use |
CA1303511C (en) * | 1987-04-20 | 1992-06-16 | Richard C. Fuisz | Spun fibrous cosmetic and method of use |
US4855326A (en) * | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
ZA882770B (en) * | 1987-04-20 | 1988-10-21 | C. Fuisz Richard | A spun fibrous cosmetic and method of use |
US5236734A (en) * | 1987-04-20 | 1993-08-17 | Fuisz Technologies Ltd. | Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix |
US4873085A (en) * | 1987-04-20 | 1989-10-10 | Fuisz Pharmaceutical Ltd. | Spun fibrous cosmetic and method of use |
US5096492A (en) * | 1987-04-20 | 1992-03-17 | Fuisz Technologies Ltd. | Dispersed systems and method of manufacture |
IL86052A (en) * | 1987-04-20 | 1991-09-16 | Fuisz Richard C | Spun fibrous cosmetic compositions |
US4997856A (en) * | 1987-04-20 | 1991-03-05 | Fuisz Pharmaceutical Ltd. | Method of producing compacted dispersable systems |
AU609137B2 (en) * | 1987-04-20 | 1991-04-26 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
ZA882771B (en) * | 1987-04-20 | 1988-10-21 | C. Fuisz Richard | Rapidly dissoluble medicinal dosage unit and method of manufacture |
IL86053A (en) * | 1987-04-20 | 1991-09-16 | Fuisz Richard C | Rapidly dissolving pharmaceutical composition comprising a medicament incorporated in spun fibers |
US5028632A (en) * | 1987-04-20 | 1991-07-02 | Fuisz Pharmaceutical Ltd. | Taste masked medicated pharmaceutical |
US5011532A (en) * | 1988-03-18 | 1991-04-30 | Fuisz Pharmaceutical Ltd. | Dispersed systems and method of manufacture |
ZA899318B (en) * | 1988-12-13 | 1990-09-26 | Fuisz Pharmaceutical Ltd | Dispersed systems and method of manufacture |
US5034421A (en) * | 1988-12-13 | 1991-07-23 | Fuisz Pharmaceutical Ltd. | Moderated spun fibrous system and method of manufacture |
US5089606A (en) * | 1989-01-24 | 1992-02-18 | Minnesota Mining And Manufacturing Company | Water-insoluble polysaccharide hydrogel foam for medical applications |
EP0387950A1 (en) * | 1989-03-13 | 1990-09-19 | Stork Friesland B.V. | Spray drying apparatus; method for preparation of a spray-dried product having a desired bulk density |
ZA902139B (en) * | 1989-03-20 | 1990-12-28 | Fuisz Pharmaceutical Ltd | A moderated spun fibrous system and method of manufacture |
US4978537A (en) * | 1989-04-19 | 1990-12-18 | Wm. Wrigley Jr. Company | Gradual release structures for chewing gum |
US5094872A (en) * | 1989-07-19 | 1992-03-10 | American Maize-Products Company | Method for making a reduced fat product |
US5073387A (en) * | 1990-01-24 | 1991-12-17 | Lafayette Applied Chemistry, Inc. | Method for preparing reduced calorie foods |
US5084295A (en) * | 1990-02-02 | 1992-01-28 | The Procter & Gamble Company | Process for making low calorie fat-containing frozen dessert products having smooth, creamy, nongritty mouthfeel |
US5082684A (en) * | 1990-02-05 | 1992-01-21 | Pfizer Inc. | Low-calorie fat substitute |
WO1991018613A1 (en) * | 1990-06-01 | 1991-12-12 | Research Corporation Technologies, Inc. | Self-emulsifying glasses |
ZA908406B (en) * | 1990-10-19 | 1991-08-28 | Fuisz Pharmaceutical Ltd | Taste masked medicated floss |
US5082682A (en) * | 1990-11-09 | 1992-01-21 | Fantasy Flavors, Inc. | Nonfat frozen dairy dessert with method and premix therefor |
US5464632A (en) * | 1991-07-22 | 1995-11-07 | Laboratoires Prographarm | Rapidly disintegratable multiparticular tablet |
US5464632C1 (en) * | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
US5709876A (en) * | 1991-10-25 | 1998-01-20 | Fuisz Technologies Ltd. | Saccharide-based matrix |
US5654003A (en) * | 1992-03-05 | 1997-08-05 | Fuisz Technologies Ltd. | Process and apparatus for making tablets and tablets made therefrom |
US5501858A (en) * | 1992-05-12 | 1996-03-26 | Fuisz Technologies Ltd. | Rapidly dispersable compositions containing polydextrose |
US5587172A (en) * | 1993-09-10 | 1996-12-24 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US5705183A (en) * | 1994-11-16 | 1998-01-06 | Phillips Company | Cotton candy coated medication and a method for making and administering the same |
Non-Patent Citations (22)
Title |
---|
A.D. Randolph, et al., "Continuous Sucrose Nucleation," The International Sugar Journal, pp. 35-38 (1974). |
A.D. Randolph, et al., "Continuous Sucrose Nucleation," The International Sugar Journal, pp. 73-77 (1974). |
A.D. Randolph, et al., "Continuous Sucrose Nucleation," The International Sugar Journal, pp. 8-12 (1974). |
A.D. Randolph, et al., Continuous Sucrose Nucleation, The International Sugar Journal, pp. 35 38 (1974). * |
A.D. Randolph, et al., Continuous Sucrose Nucleation, The International Sugar Journal, pp. 73 77 (1974). * |
A.D. Randolph, et al., Continuous Sucrose Nucleation, The International Sugar Journal, pp. 8 12 (1974). * |
Domino Sugar Corporation, "Co-crystallization". |
Domino Sugar Corporation, "Molasses Dark." |
Domino Sugar Corporation, "Raspberry." |
Domino Sugar Corporation, Co crystallization . * |
Domino Sugar Corporation, Molasses Dark. * |
Domino Sugar Corporation, Raspberry. * |
ICI Americas Inc., "ICI Americas Products for Cosmetic and Pharmaceuticals," (1977). |
ICI Americas Inc., ICI Americas Products for Cosmetic and Pharmaceuticals, (1977). * |
K.B. Domovs, et al., "Methanol-Soluble Complexes of Lactose and of other Carbohydrates," J. Dairy Science, 43, pp. 1216-1223 (1960). |
K.B. Domovs, et al., Methanol Soluble Complexes of Lactose and of other Carbohydrates, J. Dairy Science, 43, pp. 1216 1223 (1960). * |
P. Bennema, "Surface Diffusion and the Growth of Sucrose Crystals," Journal of Crystal Growth, 3,4 pp. 331-334 (1968). |
P. Bennema, Surface Diffusion and the Growth of Sucrose Crystals, Journal of Crystal Growth, 3,4 pp. 331 334 (1968). * |
R.H. Doremus, "Crystallization of Sucrose From Aqueous Solution," Journal of Colloid and Interface Science, 104, pp. 114-120 (1985). |
R.H. Doremus, Crystallization of Sucrose From Aqueous Solution, Journal of Colloid and Interface Science, 104, pp. 114 120 (1985). * |
T.D. Simpson, et al., "Crystalline Forms of Lactose Produced in Acidic Alcoholic Media," Journal of Food Science, 47, pp. 1948-1954 (1982). |
T.D. Simpson, et al., Crystalline Forms of Lactose Produced in Acidic Alcoholic Media, Journal of Food Science, 47, pp. 1948 1954 (1982). * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108602A1 (en) * | 2000-05-19 | 2003-06-12 | Yamanouchi Pharma Technologies, Inc. | Tablets and methods for modified release of hydrophilic and other active agents |
US20020102336A1 (en) * | 2000-11-29 | 2002-08-01 | Mann Douglas G. | Method of stabilizing fruit-concentrate powders |
US6783781B2 (en) | 2000-11-29 | 2004-08-31 | Douglas G. Mann | Method of stabilizing fruit-concentrate powders |
US6887926B1 (en) | 2001-11-16 | 2005-05-03 | Oatey Co. | Bonding compositions for chlorinated polymers and methods of using the same |
WO2007102150A2 (en) * | 2006-03-09 | 2007-09-13 | Erez Sason | Method and device for flowers and plants |
WO2007102150A3 (en) * | 2006-03-09 | 2009-04-16 | Erez Sason | Method and device for flowers and plants |
US20100326454A1 (en) * | 2009-06-30 | 2010-12-30 | Fuisz Richard C | Smokeless Tobacco Product |
US9848634B2 (en) | 2009-06-30 | 2017-12-26 | Philip Morris Products S.A. | Smokeless tobacco product |
US10602769B2 (en) | 2009-06-30 | 2020-03-31 | Philip Morris Products S.A. | Smokeless tobacco product |
Also Published As
Publication number | Publication date |
---|---|
JPH08301751A (en) | 1996-11-19 |
US5567439A (en) | 1996-10-22 |
EP0711547A1 (en) | 1996-05-15 |
CA2161752A1 (en) | 1996-05-05 |
US5853762A (en) | 1998-12-29 |
US5733577A (en) | 1998-03-31 |
MX9504645A (en) | 1997-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5851552A (en) | Delivery of controlled-release system(s) | |
US6020002A (en) | Delivery of controlled-release system(s) | |
US5728400A (en) | Apparatus and process for strengthening low density compression dosage units and product therefrom | |
US5622719A (en) | Process and apparatus for making rapidly dissolving dosage units and product therefrom | |
US5851553A (en) | Process and apparatus for making rapidly dissolving dosage units and product therefrom | |
US5587172A (en) | Process for forming quickly dispersing comestible unit and product therefrom | |
US5965162A (en) | Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom | |
US6284270B1 (en) | Means for creating a mass having structural integrity | |
US5654003A (en) | Process and apparatus for making tablets and tablets made therefrom | |
US6048541A (en) | Fast-dissolving comestible units formed under high-speed/high-pressure conditions | |
RU2189227C2 (en) | Quickly decomposing, pressed in forms materials and method of their preparing | |
US5935600A (en) | Process for forming chewable quickly dispersing comestible unit and product therefrom | |
EP0764019B1 (en) | Process and apparatus for making rapidly dissolving dosage units and product therefrom | |
MXPA95004645A (en) | Delivery of system (s) of release control | |
MXPA96006372A (en) | Edible unit of rapid dispersion and produ | |
MXPA96006373A (en) | Process and apparatus for doing dosing units of quick dissolution and product apparatus of the |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: BIOVAIL LABORATORIES INTERNATIONAL SRL, BARBADOS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOVAIL TECHNOLOGIES LIMITED;REEL/FRAME:019562/0470 Effective date: 20070110 Owner name: BIOVAIL LABORATORIES INTERNATIONAL SRL,BARBADOS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOVAIL TECHNOLOGIES LIMITED;REEL/FRAME:019562/0470 Effective date: 20070110 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL Free format text: SECURITY AGREEMENT;ASSIGNORS:BIOVAIL INTERNATIONAL LABORATORIES SRL;BIOVAIL INTERNATIONAL LABORATORIES (BARBADOS) SRL;REEL/FRAME:025084/0022 Effective date: 20100928 |
|
AS | Assignment |
Owner name: BIOVAIL INTERNATIONAL LABORATORIES SRL, BARBADOS Free format text: PATENT SECURITY RELEASE AGREEMENT;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS LLC;REEL/FRAME:025950/0073 Effective date: 20110308 Owner name: BIOVAIL INTERNATIONAL LABORATORIES (BARBADOS) SRL, Free format text: PATENT SECURITY RELEASE AGREEMENT;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS LLC;REEL/FRAME:025950/0073 Effective date: 20110308 |
|
AS | Assignment |
Owner name: VALEANT INTERNATIONAL (BARBADOS) SRL, BARBADOS Free format text: CHANGE OF NAME;ASSIGNOR:BIOVAIL LABORATORIES INTERNATIONAL SRL;REEL/FRAME:026404/0095 Effective date: 20110308 |
|
AS | Assignment |
Owner name: CHANTILLY BIOPHARMA LLC, VIRGINIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VALEANT INTERNATIONAL (BARBADOS) SRL;REEL/FRAME:026865/0563 Effective date: 20110408 |
|
AS | Assignment |
Owner name: VALEANT INTERNATIONAL BERMUDA, BERMUDA Free format text: CHANGE IN NAME AND COUNTRY OF INCORPORATION;ASSIGNOR:VALEANT INTERNATIONAL (BARBADOS) SRL;REEL/FRAME:028757/0052 Effective date: 20120703 |